Treatment with APR-246 can affect inflammation directly through enhanced p53 signaling in T cells and TAMs, or indirectly via non–cell autonomous effects of the drug on tumor or stromal cells of the TME or via off-target effects. Here, TP53 is linked to neoplasm.